东方生物
(688298)
| 流通市值：37.28亿 | | | 总市值：37.28亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 717,529,186.54 | 464,165,739.75 | 256,264,814.4 | 947,379,903.5 |
| 营业收入 | 717,529,186.54 | 464,165,739.75 | 256,264,814.4 | 947,379,903.5 |
| 二、营业总成本 | 993,939,164.06 | 666,531,461.19 | 346,307,060.81 | 1,341,786,186.68 |
| 营业成本 | 404,920,357.69 | 261,701,203.62 | 146,343,305.53 | 560,899,414.12 |
| 税金及附加 | 14,179,912.72 | 9,847,496.27 | 4,781,421.33 | 19,874,555.65 |
| 销售费用 | 121,886,624.41 | 81,671,910.31 | 42,942,552.49 | 190,988,640.32 |
| 管理费用 | 288,614,550.77 | 199,149,567.36 | 92,700,153.02 | 402,307,015.1 |
| 研发费用 | 119,144,388.14 | 80,145,608.88 | 42,007,384.36 | 230,811,644.92 |
| 财务费用 | 45,193,330.33 | 34,015,674.75 | 17,532,244.08 | -63,095,083.43 |
| 其中:利息费用 | 7,268,063.05 | 4,981,784.68 | 2,515,595.17 | 9,908,990.32 |
| 其中:利息收入 | 63,877,627.4 | 50,000,713.68 | 32,802,993.74 | 80,351,790.22 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,665,803.79 | 1,245,811.82 | 3,038,506.56 | -1,596,613.77 |
| 加:投资收益 | 9,707,564.28 | 11,913,758.29 | 7,098,406.57 | 8,681,541.5 |
| 净敞口套期收益 | - | - | - | 0 |
| 汇兑收益 | - | - | - | 0 |
| 资产处置收益 | 1,223,395.93 | 1,121,234.68 | 573,989.4 | 1,748,605.93 |
| 资产减值损失(新) | -17,811,136.43 | -13,558,090.52 | -11,642,070.82 | -199,366,343.14 |
| 信用减值损失(新) | -3,217,573.03 | -4,150,220.22 | -4,004,163.41 | -7,919,960.07 |
| 其他收益 | 5,275,763.69 | 3,461,719.93 | 2,161,269.36 | 10,614,265.82 |
| 四、营业利润 | -277,566,159.29 | -202,331,507.46 | -92,816,308.75 | -582,244,786.91 |
| 加:营业外收入 | 354,865.62 | 164,094.71 | 2,826.09 | 776,755.75 |
| 减:营业外支出 | 2,512,404.21 | 1,162,433.97 | 12,404.11 | 2,025,806.33 |
| 五、利润总额 | -279,723,697.88 | -203,329,846.72 | -92,825,886.77 | -583,493,837.49 |
| 减:所得税费用 | 31,148,080.54 | 28,731,150.34 | 5,875,309.3 | 13,911,370.06 |
| 六、净利润 | -310,871,778.42 | -232,060,997.06 | -98,701,196.07 | -597,405,207.55 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -310,871,778.42 | -232,060,997.06 | -98,701,196.07 | -597,405,207.55 |
| 终止经营净利润 | - | - | - | 0 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -297,299,261.66 | -222,229,817.44 | -93,843,129.17 | -573,598,190.08 |
| 少数股东损益 | -13,572,516.76 | -9,831,179.62 | -4,858,066.9 | -23,807,017.47 |
| 扣除非经常损益后的净利润 | -314,973,768.68 | -237,982,747.33 | -105,413,891.47 | -597,472,097.82 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -1.55 | -1.16 | -0.49 | -2.98 |
| (二)稀释每股收益 | -1.55 | -1.16 | -0.49 | -2.98 |
| 八、其他综合收益 | -21,879,142.42 | -16,066,354.42 | -4,955,418.9 | -28,782,723.77 |
| 归属于母公司股东的其他综合收益 | -21,879,142.42 | -16,066,354.42 | -4,955,418.9 | -28,782,723.77 |
| 九、综合收益总额 | -332,750,920.84 | -248,127,351.48 | -103,656,614.97 | -626,187,931.32 |
| 归属于母公司股东的综合收益总额 | -319,178,404.08 | -238,296,171.86 | -98,798,548.07 | -602,380,913.85 |
| 归属于少数股东的综合收益总额 | -13,572,516.76 | -9,831,179.62 | -4,858,066.9 | -23,807,017.47 |
| 公告日期 | 2026-10-29 | 2026-08-29 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |